US Stock MarketDetailed Quotes

RDY Dr. Reddy's Laboratories

Watchlist
  • 14.140
  • -0.180-1.26%
Close Nov 26 16:00 ET
  • 14.150
  • +0.010+0.07%
Post 20:02 ET
11.78BMarket Cap18.63P/E (TTM)

Dr. Reddy's Laboratories Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Quarterly+Annual
YOY yoy
Hide blank lines yoy
(Q2)Sep 30, 2024
(Q1)Jun 30, 2024
(FY)Mar 31, 2024
(Q4)Mar 31, 2024
(Q3)Dec 31, 2023
(Q2)Sep 30, 2023
(Q1)Jun 30, 2023
(FY)Mar 31, 2023
(Q4)Mar 31, 2023
(Q3)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities
-48.03%9.32B
-24.48%8.5B
-22.83%45.43B
-41.46%11.52B
-79.63%4.74B
93.15%17.93B
69.05%11.25B
109.46%58.88B
3,218.55%19.68B
-10.04%23.26B
Net income from continuing operations
-9.36%13.42B
-0.75%13.92B
23.56%55.68B
36.26%13.07B
10.57%13.79B
33.00%14.8B
18.10%14.03B
91.22%45.07B
996.23%9.59B
76.52%12.47B
Operating gains losses
79.98%-221M
126.61%161M
-43.60%-1.58B
60.50%-158M
250.53%286M
-135.23%-1.1B
83.40%-605M
57.46%-1.1B
14.89%-400M
-30.14%-190M
Depreciation and amortization
4.91%3.98B
6.75%3.81B
17.45%14.84B
16.43%3.71B
15.26%3.77B
21.21%3.79B
17.02%3.57B
6.87%12.64B
7.81%3.19B
9.91%3.27B
Deferred tax
32.72%5.75B
10.43%4.9B
5.79%16.19B
-19.57%2.95B
15.30%4.47B
-13.02%4.33B
59.70%4.44B
75.26%15.3B
127.80%3.66B
46.56%3.88B
Other non cash items
125.14%92M
-447.62%-146M
-328.63%-567M
55.00%-54M
-230.34%-189M
-493.55%-366M
-67.69%42M
3,642.86%248M
-101.40%-120M
101.69%145M
Change In working capital
-398.35%-7.78B
-60.77%-13.14B
-156.93%-20.18B
-142.05%-2.76B
-354.13%-11.86B
123.12%2.61B
-4.77%-8.17B
57.54%-7.86B
144.81%6.57B
-69.27%4.67B
-Change in receivables
-146.29%-3.4B
83.09%-786M
-40.02%-8.05B
-177.11%-1.92B
-561.61%-8.83B
297.68%7.34B
27.83%-4.65B
66.19%-5.75B
159.98%2.49B
-68.98%1.91B
-Change in inventory
-6.51%-5.01B
-36.33%-6.32B
-594.99%-18.45B
-3,124.79%-3.9B
-216.68%-5.2B
-471.70%-4.7B
-115.22%-4.64B
73.22%-2.65B
99.15%-121M
-119.21%-1.64B
-Change in payables and accrued expense
-32.47%1.58B
11.47%2.48B
14,943.48%3.46B
-290.10%-1.5B
-85.88%390M
228.65%2.34B
516.48%2.22B
-99.48%23M
-138.59%-384M
282.14%2.76B
-Change in other working capital
59.35%-963M
-664.69%-8.51B
441.10%2.86B
-0.72%4.56B
9.25%1.78B
66.25%-2.37B
-183.94%-1.11B
-86.85%528M
72.16%4.59B
-17.65%1.63B
Cash from discontinued investing activities
Operating cash flow
-48.03%9.32B
-24.48%8.5B
-22.83%45.43B
-41.46%11.52B
-79.63%4.74B
93.15%17.93B
69.05%11.25B
109.46%58.88B
115.80%19.68B
34.21%23.26B
Investing cash flow
Cash flow from continuing investing activities
-322.21%-19.07B
-145.85%-20.25B
2.63%-40.28B
28.04%-11.35B
38.74%-16.18B
-178.79%-4.52B
-67.30%-8.24B
-56.79%-41.37B
28.27%-15.77B
-856.54%-26.41B
Capital expenditure reported
----
----
----
----
----
----
----
----
----
30.73%-3.1B
Net PPE purchase and sale
-127.77%-7.33B
-35.64%-4.91B
-36.46%-15.34B
-44.73%-16.35B
97,987.50%7.85B
-2,354.96%-3.22B
-2,122.35%-3.62B
21.34%-11.24B
21.99%-11.3B
-78.38%8M
Net intangibles purchase and sale
119.66%46M
84.60%-1.31B
-45.98%-11.01B
-46.25%-11.03B
--8.79B
---234M
---8.53B
-422.73%-7.54B
-71.86%-7.54B
--0
Net business purchase and sale
----
----
---12M
--0
---12M
----
----
--0
--0
----
Net investment purchase and sale
2,338.67%39.13B
-507.03%-14.47B
32.79%-15.7B
54.80%-5.55B
49.05%-11.96B
-119.68%-1.75B
1.43%3.56B
-108.61%-23.37B
31.87%-12.27B
-1,759.36%-23.48B
Cash from discontinued investing activities
Investing cash flow
-322.21%-19.07B
-145.85%-20.25B
2.63%-40.28B
28.04%-11.35B
38.74%-16.18B
-178.79%-4.52B
-67.30%-8.24B
-56.79%-41.37B
28.27%-15.77B
-856.54%-26.41B
Financing cash flow
Cash flow from continuing financing activities
329.53%16.15B
746.41%9.54B
85.99%-3.76B
87.60%-533M
806.00%5.28B
43.01%-7.04B
86.33%-1.48B
-1,009.04%-26.86B
-184.32%-4.3B
122.70%583M
Net issuance payments of debt
2,920.27%16.56B
1,135.92%10.27B
121.31%4.35B
102.64%109M
431.54%5.82B
91.70%-587M
90.37%-991M
-845.78%-20.4B
-176.45%-4.13B
149.80%1.09B
Net common stock issuance
948.69%7.19B
-75.95%19M
118.75%805M
-85.97%31M
-88.89%9M
1,860.00%686M
154.84%79M
10.18%368M
2,662.50%221M
80.00%81M
Cash dividends paid
-0.21%-6.66B
--0
-33.52%-6.65B
--0
--0
-33.52%-6.65B
--0
-20.09%-4.98B
--0
--0
Cash from discontinued financing activities
Financing cash flow
329.53%16.15B
746.41%9.54B
85.99%-3.76B
87.60%-533M
806.00%5.28B
43.01%-7.04B
86.33%-1.48B
-1,009.04%-26.86B
-184.32%-4.3B
122.70%583M
Net cash flow
Beginning cash position
-32.03%4.91B
22.98%7.11B
-61.09%5.78B
20.39%7.54B
48.85%13.54B
14.78%7.23B
-61.09%5.78B
0.22%14.85B
-71.52%6.26B
-8.89%9.09B
Current changes in cash
0.35%6.4B
-243.76%-2.21B
114.82%1.39B
7.40%-363M
-140.01%-6.16B
138.87%6.37B
116.96%1.54B
-1,235.09%-9.36B
94.96%-392M
-121.39%-2.57B
Effect of exchange rate changes
65.15%-23M
119.10%17M
-120.63%-59M
26.14%-65M
160.30%161M
-151.56%-66M
-117.35%-89M
-60.98%286M
-113.58%-88M
-4,350.00%-267M
End cash Position
-16.62%11.29B
-32.03%4.91B
22.98%7.11B
22.98%7.11B
20.39%7.54B
48.85%13.54B
14.78%7.23B
-61.09%5.78B
-61.09%5.78B
-71.52%6.26B
Free cash flow
-89.94%1.41B
324.97%2.07B
-55.02%18B
-67.13%5.24B
-101.51%-305M
135.00%13.99B
54.74%-921M
341.65%40.01B
212.86%15.93B
56.81%20.16B
Currency Unit
INR
INR
INR
INR
INR
INR
INR
INR
INR
INR
Accounting Standards
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
US-GAAP
Audit Opinions
--
--
Unqualified Opinion
--
--
--
--
Unqualified Opinion
--
--
(Q2)Sep 30, 2024(Q1)Jun 30, 2024(FY)Mar 31, 2024(Q4)Mar 31, 2024(Q3)Dec 31, 2023(Q2)Sep 30, 2023(Q1)Jun 30, 2023(FY)Mar 31, 2023(Q4)Mar 31, 2023(Q3)Dec 31, 2022
Operating Cash Flow (Indirect Method)
Cash flow from continuing operating activities -48.03%9.32B-24.48%8.5B-22.83%45.43B-41.46%11.52B-79.63%4.74B93.15%17.93B69.05%11.25B109.46%58.88B3,218.55%19.68B-10.04%23.26B
Net income from continuing operations -9.36%13.42B-0.75%13.92B23.56%55.68B36.26%13.07B10.57%13.79B33.00%14.8B18.10%14.03B91.22%45.07B996.23%9.59B76.52%12.47B
Operating gains losses 79.98%-221M126.61%161M-43.60%-1.58B60.50%-158M250.53%286M-135.23%-1.1B83.40%-605M57.46%-1.1B14.89%-400M-30.14%-190M
Depreciation and amortization 4.91%3.98B6.75%3.81B17.45%14.84B16.43%3.71B15.26%3.77B21.21%3.79B17.02%3.57B6.87%12.64B7.81%3.19B9.91%3.27B
Deferred tax 32.72%5.75B10.43%4.9B5.79%16.19B-19.57%2.95B15.30%4.47B-13.02%4.33B59.70%4.44B75.26%15.3B127.80%3.66B46.56%3.88B
Other non cash items 125.14%92M-447.62%-146M-328.63%-567M55.00%-54M-230.34%-189M-493.55%-366M-67.69%42M3,642.86%248M-101.40%-120M101.69%145M
Change In working capital -398.35%-7.78B-60.77%-13.14B-156.93%-20.18B-142.05%-2.76B-354.13%-11.86B123.12%2.61B-4.77%-8.17B57.54%-7.86B144.81%6.57B-69.27%4.67B
-Change in receivables -146.29%-3.4B83.09%-786M-40.02%-8.05B-177.11%-1.92B-561.61%-8.83B297.68%7.34B27.83%-4.65B66.19%-5.75B159.98%2.49B-68.98%1.91B
-Change in inventory -6.51%-5.01B-36.33%-6.32B-594.99%-18.45B-3,124.79%-3.9B-216.68%-5.2B-471.70%-4.7B-115.22%-4.64B73.22%-2.65B99.15%-121M-119.21%-1.64B
-Change in payables and accrued expense -32.47%1.58B11.47%2.48B14,943.48%3.46B-290.10%-1.5B-85.88%390M228.65%2.34B516.48%2.22B-99.48%23M-138.59%-384M282.14%2.76B
-Change in other working capital 59.35%-963M-664.69%-8.51B441.10%2.86B-0.72%4.56B9.25%1.78B66.25%-2.37B-183.94%-1.11B-86.85%528M72.16%4.59B-17.65%1.63B
Cash from discontinued investing activities
Operating cash flow -48.03%9.32B-24.48%8.5B-22.83%45.43B-41.46%11.52B-79.63%4.74B93.15%17.93B69.05%11.25B109.46%58.88B115.80%19.68B34.21%23.26B
Investing cash flow
Cash flow from continuing investing activities -322.21%-19.07B-145.85%-20.25B2.63%-40.28B28.04%-11.35B38.74%-16.18B-178.79%-4.52B-67.30%-8.24B-56.79%-41.37B28.27%-15.77B-856.54%-26.41B
Capital expenditure reported ------------------------------------30.73%-3.1B
Net PPE purchase and sale -127.77%-7.33B-35.64%-4.91B-36.46%-15.34B-44.73%-16.35B97,987.50%7.85B-2,354.96%-3.22B-2,122.35%-3.62B21.34%-11.24B21.99%-11.3B-78.38%8M
Net intangibles purchase and sale 119.66%46M84.60%-1.31B-45.98%-11.01B-46.25%-11.03B--8.79B---234M---8.53B-422.73%-7.54B-71.86%-7.54B--0
Net business purchase and sale -----------12M--0---12M----------0--0----
Net investment purchase and sale 2,338.67%39.13B-507.03%-14.47B32.79%-15.7B54.80%-5.55B49.05%-11.96B-119.68%-1.75B1.43%3.56B-108.61%-23.37B31.87%-12.27B-1,759.36%-23.48B
Cash from discontinued investing activities
Investing cash flow -322.21%-19.07B-145.85%-20.25B2.63%-40.28B28.04%-11.35B38.74%-16.18B-178.79%-4.52B-67.30%-8.24B-56.79%-41.37B28.27%-15.77B-856.54%-26.41B
Financing cash flow
Cash flow from continuing financing activities 329.53%16.15B746.41%9.54B85.99%-3.76B87.60%-533M806.00%5.28B43.01%-7.04B86.33%-1.48B-1,009.04%-26.86B-184.32%-4.3B122.70%583M
Net issuance payments of debt 2,920.27%16.56B1,135.92%10.27B121.31%4.35B102.64%109M431.54%5.82B91.70%-587M90.37%-991M-845.78%-20.4B-176.45%-4.13B149.80%1.09B
Net common stock issuance 948.69%7.19B-75.95%19M118.75%805M-85.97%31M-88.89%9M1,860.00%686M154.84%79M10.18%368M2,662.50%221M80.00%81M
Cash dividends paid -0.21%-6.66B--0-33.52%-6.65B--0--0-33.52%-6.65B--0-20.09%-4.98B--0--0
Cash from discontinued financing activities
Financing cash flow 329.53%16.15B746.41%9.54B85.99%-3.76B87.60%-533M806.00%5.28B43.01%-7.04B86.33%-1.48B-1,009.04%-26.86B-184.32%-4.3B122.70%583M
Net cash flow
Beginning cash position -32.03%4.91B22.98%7.11B-61.09%5.78B20.39%7.54B48.85%13.54B14.78%7.23B-61.09%5.78B0.22%14.85B-71.52%6.26B-8.89%9.09B
Current changes in cash 0.35%6.4B-243.76%-2.21B114.82%1.39B7.40%-363M-140.01%-6.16B138.87%6.37B116.96%1.54B-1,235.09%-9.36B94.96%-392M-121.39%-2.57B
Effect of exchange rate changes 65.15%-23M119.10%17M-120.63%-59M26.14%-65M160.30%161M-151.56%-66M-117.35%-89M-60.98%286M-113.58%-88M-4,350.00%-267M
End cash Position -16.62%11.29B-32.03%4.91B22.98%7.11B22.98%7.11B20.39%7.54B48.85%13.54B14.78%7.23B-61.09%5.78B-61.09%5.78B-71.52%6.26B
Free cash flow -89.94%1.41B324.97%2.07B-55.02%18B-67.13%5.24B-101.51%-305M135.00%13.99B54.74%-921M341.65%40.01B212.86%15.93B56.81%20.16B
Currency Unit INRINRINRINRINRINRINRINRINRINR
Accounting Standards US-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAPUS-GAAP
Audit Opinions ----Unqualified Opinion--------Unqualified Opinion----

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data

Investment Theme Infectious Disease
Infectious Disease
Intraday-0.19%
Cannabis & Hemp
Cannabis & Hemp
Intraday-0.78%